Literature DB >> 34151458

Diagnosis of melanoma by imaging mass spectrometry: Development and validation of a melanoma prediction model.

Rami N Al-Rohil1, Jessica L Moore2, Nathan Heath Patterson2,3, Sarah Nicholson2, Nico Verbeeck4, Marc Claesen4, Jameelah Z Muhammad2, Richard M Caprioli2,3, Jeremy L Norris2,3, Sara Kantrow5, Margaret Compton6, Jason Robbins5, Ahmed K Alomari7.   

Abstract

BACKGROUND: The definitive diagnosis of melanocytic neoplasia using solely histopathologic evaluation can be challenging. Novel techniques that objectively confirm diagnoses are needed. This study details the development and validation of a melanoma prediction model from spatially resolved multivariate protein expression profiles generated by imaging mass spectrometry (IMS).
METHODS: Three board-certified dermatopathologists blindly evaluated 333 samples. Samples with triply concordant diagnoses were included in this study, divided into a training set (n = 241) and a test set (n = 92). Both the training and test sets included various representative subclasses of unambiguous nevi and melanomas. A prediction model was developed from the training set using a linear support vector machine classification model.
RESULTS: We validated the prediction model on the independent test set of 92 specimens (75 classified correctly, 2 misclassified, and 15 indeterminate). IMS detects melanoma with a sensitivity of 97.6% and a specificity of 96.4% when evaluating each unique spot. IMS predicts melanoma at the sample level with a sensitivity of 97.3% and a specificity of 97.5%. Indeterminate results were excluded from sensitivity and specificity calculations.
CONCLUSION: This study provides evidence that IMS-based proteomics results are highly concordant to diagnostic results obtained by careful histopathologic evaluation from a panel of expert dermatopathologists.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  MALDI IMS; diagnostic test; imaging mass spectrometry; melanoma; proteomics

Mesh:

Year:  2021        PMID: 34151458      PMCID: PMC8595555          DOI: 10.1111/cup.14083

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  47 in total

1.  Agreement of dermatopathologists in the evaluation of clinically difficult melanocytic lesions: how golden is the 'gold standard'?

Authors:  R P Braun; D Gutkowicz-Krusin; H Rabinovitz; A Cognetta; R Hofmann-Wellenhof; V Ahlgrimm-Siess; D Polsky; M Oliviero; I Kolm; P Googe; R King; V G Prieto; L French; A Marghoob; M Mihm
Journal:  Dermatology       Date:  2012-03-20       Impact factor: 5.366

2.  MALDI-Imaging for Classification of Epithelial Ovarian Cancer Histotypes from a Tissue Microarray Using Machine Learning Methods.

Authors:  Oliver Klein; Frederic Kanter; Hagen Kulbe; Paul Jank; Carsten Denkert; Grit Nebrich; Wolfgang D Schmitt; Zhiyang Wu; Catarina A Kunze; Jalid Sehouli; Silvia Darb-Esfahani; Ioana Braicu; Jan Lellmann; Herbert Thiele; Eliane T Taube
Journal:  Proteomics Clin Appl       Date:  2018-12-14       Impact factor: 3.494

3.  Histology-directed and imaging mass spectrometry: An emerging technology in ectopic calcification.

Authors:  Domenico Taverna; Federica Boraldi; Giorgio De Santis; Richard M Caprioli; Daniela Quaglino
Journal:  Bone       Date:  2015-01-13       Impact factor: 4.398

4.  Spatial mapping by imaging mass spectrometry offers advancements for rapid definition of human skin proteomic signatures.

Authors:  Domenico Taverna; Lillian B Nanney; Alonda C Pollins; Giovanni Sindona; Richard Caprioli
Journal:  Exp Dermatol       Date:  2011-05-04       Impact factor: 3.960

Review 5.  Practical application of new technologies for melanoma diagnosis: Part II. Molecular approaches.

Authors:  Jordon March; Matthew Hand; Amanda Truong; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2015-06       Impact factor: 11.527

Review 6.  MALDI imaging mass spectrometry in cancer research: combining proteomic profiling and histological evaluation.

Authors:  Cédrik Schöne; Heinz Höfler; Axel Walch
Journal:  Clin Biochem       Date:  2013-02-04       Impact factor: 3.281

7.  Next Generation Histology-Directed Imaging Mass Spectrometry Driven by Autofluorescence Microscopy.

Authors:  Nathan Heath Patterson; Michael Tuck; Adam Lewis; Alexis Kaushansky; Jeremy L Norris; Raf Van de Plas; Richard M Caprioli
Journal:  Anal Chem       Date:  2018-10-16       Impact factor: 6.986

Review 8.  Through the looking glass and what you find there: making sense of comparative genomic hybridization and fluorescence in situ hybridization for melanoma diagnosis.

Authors:  Jayson Miedema; Aleodor A Andea
Journal:  Mod Pathol       Date:  2020-02-17       Impact factor: 7.842

9.  Immunohistochemistry utilization in the diagnosis of melanoma.

Authors:  Matthew S Dinehart; Scott M Dinehart; Suporn Sukpraprut-Braaten; Whitney A High
Journal:  J Cutan Pathol       Date:  2020-01-27       Impact factor: 1.587

10.  Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma.

Authors:  Loren E Clarke; M B Warf; Darl D Flake; Anne-Renee Hartman; Steven Tahan; Christopher R Shea; Pedram Gerami; Jane Messina; Scott R Florell; Richard J Wenstrup; Kristen Rushton; Kirstin M Roundy; Colleen Rock; Benjamin Roa; Kathryn A Kolquist; Alexander Gutin; Steven Billings; Sancy Leachman
Journal:  J Cutan Pathol       Date:  2015-04-13       Impact factor: 1.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.